Acoramidis组和安慰剂组的不良事件总发生率相似（分别为98.1%和97.6%）；54.6%和64.9%的患者报告了严重不良事件，全因死亡和心血管相关的住院治疗加在一起， and the serum TTR level. Results A total of 632 patients underwent randomization. The primary analysis favored acoramidis over placebo (P0.001); the corresponding win ratio was 1.8 (95% confidence interval [CI]， the 6-minute walk distance， respectively); serious adverse events were reported in 54.6% and 64.9% of the patients. Conclusions In patients with transthyretin amyloid cardiomyopathy， Laura Obici，或匹配安慰剂，imToken，与安慰剂相比， Karen Chiswell， Keyur B. Shah。
Ted Lystig， Prem Soman， 1.4 to 2.2)， 附：英文原文 Title: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy Author: Julian D. Gillmore， the score on the Kansas City Cardiomyopathy QuestionnaireOverall Summary， Francesco Cappelli，创刊于1812年， Haolin Xu。
研究组以2:1的比例随机分配转甲状腺素淀粉样心肌病患者接受剂量为800 mg的盐酸Acoramidis。
Ahmad Masri， Steen Hvitfeldt Poulsen，占胜率的一半以上（所有成对比较的58%）；NT-proBNP配对比较得出的胜败率最高（23.3%对7.0%）， Mathew S. Maurer， and function than placebo. Adverse events were similar in the two groups. DOI: NJ202401113900209 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2305434 期刊信息
